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ABSTRACT
A retrospective study was performed in an Italian tertiary hospital to evaluate trends in candidaemia
between 1992 and 2001, and to compare the characteristics of episodes of fungaemia between 1992–1997
and 1998–2001. In total, 370 episodes of candidaemia were identified, with an average incidence of 0.99
episodes ⁄ 10 000 patient-days ⁄ year (range 0.49–1.29 episodes). On an annual trend basis, the overall
incidence was essentially stable in surgical and medical wards, but decreased in intensive care units
(ICUs) (p 0.0065). The average use of fluconazole was 37.9 g ⁄ 10 000 patient-days ⁄year (range 21.4–
56.1 g), and did not change significantly during the 10-year period. Nearly two-thirds of patients were in
ICUs at the onset of candidaemia, but none was neutropenic in either study period. Candida albicans
remained the predominant species isolated (53.8% vs. 48.1%), followed by Candida parapsilosis, Candida
glabrata and Candida tropicalis, the distribution of which did not change significantly. The 30-day crude
mortality rate was essentially similar (44% vs. 35%) in both study periods. Thus the incidence of
nosocomial candidaemia, although high in this institution, decreased among critically-ill patients during
the 10-year period. This finding seemed to be related to an improvement in infection control practices,
particularly regarding the prevention of intravascular catheter-related infections in ICUs. Although the
overall use of fluconazole was considerable, no increase in azole-resistant non-albicans Candida spp. was
detected.
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INTRODUCTION
Data from the last two decades clearly indicate
an increasing frequency of nosocomial fungal
infections among hospitalised patients. This phe-
nomenon has been ascribed to several factors,
including use of immunosuppressive and
chemotherapeutic agents, extensive surgery or
burns, broad-spectrum antibiotics, invasive mon-
itoring devices, long-term central venous cathe-
ters (CVCs) and hyper-alimentation fluids [1].
Invasive candidiasis remains the most common
fungal infection in immunocompromised
patients, and has acquired increasing importance
among critically-ill non-immunosuppressed pa-
tients [2]. Candidaemia represents 10–20% of all
invasive episodes of candidiasis, and is associ-
ated with extremely high mortality rates [3,4].
Although Candida albicans still ranks first, a shift
to other Candida spp. has been reported in many
series of nosocomial candidaemia [5–9]. These
changes have been attributed to the increased
use of prophylaxis with azoles, but this relation-
ship remains controversial [10].
Candida spp. were responsible for 5–10% of all
bloodstream infections (BSIs) reported from 790
intensive care units (ICUs) to the USA National
Nosocomial Infection Surveillance system during
the 1990s [11]. More recently, in the Surveillance
and Control of Pathogens of Epidemiological
Importance study during 1995–2002, Candida
spp. were reported to cause 9% of BSIs detected
in 49 USA hospitals [12]. In Europe, contrasting
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data concerning the epidemiology of candidae-
mia have been reported in recent years from
national or regional and hospital population-
based surveys, which included different types of
hospitals and differing characteristics within the
patient population [13–17]. During the early
1990s, the rate of candidaemia doubled in five
Dutch university hospitals, with a concomitant
increase in BSIs caused by non-albicans Candida
spp., especially C. glabrata [18]. In contrast, Swiss
investigators demonstrated a stable incidence of
candidaemia, with no shift to azole-resistant
species, in 17 tertiary-care hospitals during the
period 1991–2000 [19].
A previous study reported data from a retro-
spective survey of nosocomial candidaemia in an
Italian tertiary hospital during 1992–1997 [20].
The present study was conducted in the same
hospital, extending the survey period to 2001, to
evaluate epidemiological trends in candidaemia
during the last decade, and to compare the
characteristics of candidaemia episodes between
the two study periods.
MATERIALS AND METHODS
The study setting was a university-affiliated tertiary hospital in
Verona, Italy, which included most medical and surgical
specialties, two units for heart and kidney transplants, and a
cancer centre that admitted patients with solid tumours, but
not those with haematological malignancies. The recent study
period (B) lasted from January 1998 to December 2001, during
which the overall capacity of the hospital was c. 1100 beds,
compared to c. 1200 beds during the previously reported study
period (A) between January 1992 and December 1997. The
inclusion and stratification criteria of the patient population
have been described in detail previously [20]. In brief, an
episode of candidaemia was defined as at least one positive
blood culture yielding Candida spp. during a single period of
hospitalisation. All cases of candidaemia were identified
retrospectively through the records of the department of
microbiology. Candidaemia was considered to be persistent if
the same Candida sp. was isolated from blood cultures for at
least two consecutive days. Data concerning patient demo-
graphics and hospital ward (grouping into medical, surgical
and ICUs) at the onset of candidaemia, together with the
reason for and duration of hospitalisation, were retrieved from
the available medical records. The severity of underlying
disease was categorised according to a modification of the
McCabe scale [21], as reported previously. Concomitant
bacteraemia was defined as the isolation of bacterial species
within a 48-h period before or after the first isolation of Candida
spp. from blood culture. Data were collected concerning the
use of systemic antifungal drugs, as well as predisposing
factors, within the 3 weeks before the onset of candidaemia.
Neutropenia was defined as an absolute neutrophil count of
< 1 · 103 ⁄lL. Steroid therapy was defined as the equivalent of
25 mg of prednisone ⁄day for > 2 weeks. Candidaemia was
considered to be catheter-related if the CVC was removed and
culture of the tip yielded the same Candida sp. that was
isolated from blood culture. In addition, an investigation was
performed to determine the species and numbers of blood-
infecting Candida isolates, CVC removal, and details of
antifungal therapy for each episode of candidaemia. Crude
mortality was defined as the death rate within 30 days of the
first blood culture positive for Candida spp.
According to published guidelines [22], the following were
considered to be adequate antifungal regimens: fluconazole
‡ 6 mg ⁄ kg ⁄day; amphotericin ‡ 0.7 mg ⁄ kg ⁄day; or a lipid-
associated formulation of amphotericin B 3–5 mg ⁄ kg ⁄day.
Therapy with lower doses, or of shorter duration, as well as
therapy with other drugs, or no therapy at all, were considered
to be inadequate. Data on the annual consumption of flucon-
azole (oral plus intravenous) were obtained from the records of
the hospital pharmacy.
Statistical analysis
Epidemiological and mycological data obtained from both
cohorts were analysed by descriptive statistics. Tests of
difference between proportions were used to evaluate the
variation in categorical variables for patients belonging to
periods A and B, with p 0.05 considered to be significant. To
evaluate the incidence of candidaemia during the entire study
period (1992–2001), the total number of patient-days of
care ⁄ year, as well as the patient-days of care ⁄ year within the
medical, surgical and ICU areas, were obtained from the
institutional database. Linear trends against incidence were
analysed using simple linear regression, as well as the General
Linear Models with Poisson-dependent variable and linear-
link function, with years considered as an independent
variable, and candidaemia episodes or fluconazole consump-
tion as dependent variables. All statistical analyses were
performed with the use of Statistica v. 6 for Windows (StatSoft,
Inc., Tulsa, OK, USA).
RESULTS
During the entire study period (1992–2001), 370
episodes of candidaemia were identified through
the records of the microbiology laboratory. The
overall number of patient-days of care delivered
by this hospital decreased during the 10-year
study period from 402 906 in 1992 to 339 494 in
2001. Conversely, the number of patient-days of
care delivered in ICUs increased remarkably
during the study period, from 9501 in 1992 to
24 119 in 2001. The average incidence of candid-
aemia was 0.99 episodes ⁄ 10 000 patient-days ⁄
year, ranging from 0.49 in 1992 to 1.29 in 1995.
On an annual trend basis, the overall incidence of
candidaemia was essentially stable (p 0.798)
over the 10-year period. The incidence of infec-
tion varied according to the location of the patient
in the hospital; candidaemia occurred 105 times
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and 23 times more frequently in ICUs
(15.8 ⁄ 10 000 patient-days) than in medical
wards (0.15 ⁄ 10 000 patient-days) or surgical
wards (0.69 ⁄ 10 000 patient-days), respectively.
On an annual trend basis, the incidence of
candidaemia did not change significantly in sur-
gical (p 0.196) or medical (p 0.505) wards. Rather,
it decreased in ICUs (p 0.0065), as shown in Fig. 1.
The overall annual use of the parenteral and oral
forms of fluconazole administered ⁄ 10 000 patient-
days in 1992–2001 is illustrated in Fig. 2. The
average use of fluconazole was 37.9 g ⁄ 10 000
patient-days (range 21.4–56.1 g). The annual use
of fluconazole decreased between 1992 and 1999,
but increased subsequently; thus, the overall use
remained essentially unchanged (p 0.74) during
the 10-year period.
For the 370 episodes of candidaemia that
occurred during 1992–2001, 284 (76%) medical
charts were available for review. The charts
corresponded to 99 patients (mean age
60 ± 21 years) in period B, comprising 60 (61%)
males and 39 females, and to 185 patients (mean
age 58 ± 19 years) in period A, comprising 104
(56%) males and 81 females. The underlying
diseases that required hospitalisation, their sever-
ity according to the McCabe scale, and the
hospital wards concerned at the onset of candid-
aemia during the two study periods are shown in
Table 1. The distribution of the most common
underlying diseases and their severity were sim-
ilar for the two study periods, with the exception
of trauma and non-fatal diseases, which were
more frequent in period B than in period A. At the
onset of candidaemia, nearly two-thirds of
patients were hospitalised in ICUs, and at least
25% of patients were in surgical wards.
Comparing patients in periods A and B, the
most common predisposing factors for candidae-
mia were antibiotics (95% vs. 99%), CVC (93%
vs. 93%), bladder catheter (83% vs. 94%), total
parenteral nutrition (65% vs. 64%), steroids (38%
vs. 28%) and abdominal surgery (26% vs. 28%).
No patient was neutropenic or the recipient of a
solid organ, and none received systemic antifun-
gal prophylaxis or therapy within the 3 weeks
preceding the onset of candidaemia. All Candida
BSIs were nosocomial, and occurred 26 ± 21 and
33 ± 26 days after hospital admission in periods B
and A, respectively (p 0.02). Table 2 shows the
Fig. 1. Incidence of candidaemia among patients admitted
to intensive care units, 1992–2001. Middle line shows
simple regression; outer lines show 95% CI limits.
Fig. 2. Overall annual consumption of fluconazole, 1992–
2001. Middle line shows simple regression; outer lines
show 95% CI limits.
Table 1. Type and severity of underlying diseases, and
hospital wards in which patients were located at the onset
of candidaemia
Period A (1992–1997)
No. (%) of patients
Period B (1998–2001)
No. (%) of patients p
Underlying disease
Solid neoplasia 40 (21.6) 24 (24.2) NS
Trauma 32 (17.3) 27 (27.3) 0.050
Abdominal diseasesa 24 (13.0) 17 (17.2) NS
Cardiovascular diseases 23 (12.5) 11 (11.1) NS
Other illnessesb 66 (35.7) 20 (20.2) 0.007
Severity of underlying disease
Non-fatal 45 (24.0) 40 (40.4) 0.005
Ultimately fatal 93 (50.3) 45 (45.5) NS
Rapidly fatal 47 (25.4) 14 (14.1) 0.029
Hospital wards
ICUs 128 (69.2) 59 (59.6) NS
Surgical wards 46 (24.9) 30 (30.3) NS
Medical wards 11 (5.9) 10 (10.1) NS
ICU, intensive care unit; NS, not significant.
aAbdominal diseases requiring surgery.
bOther illnesses: period A, neurological disease (n = 19), respiratory disease
(n = 17), cirrhosis (n = 12), burns (n = 7), AIDS (n = 3), others (n = 11); period B,
respiratory disease (n = 6), neurological disease (n = 5), cirrhosis (n = 5), burns
(n = 3), others (n = 3).
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distribution of various species of Candida for the
two study periods, while Table 3 shows the
distribution of C. albicans and non-albicans Candida
spp. according to the hospital ward type. Overall,
C. albicans was the most common bloodstream
isolate detected during both periods; C. parapsilo-
sis, C. glabrata and C. tropicalis were the next most
common isolates, and their distribution did not
change significantly between the two periods. In
surgical wards, the frequency of isolation of non-
albicans Candida spp. exceeded that of C. albicans
during period B. Two or more different fungal
species (polymicrobial candidaemia) were found
in 10% of episodes during both periods, and the
mean numbers of positive fungal blood cul-
tures ⁄patient were 3 ± 2 and 3 ± 1 in periods B
and A, respectively. The mean duration of can-
didaemia was 8.0 + 5.6 days in period B, which
was significantly (p < 0.001) shorter than that
recorded in period A (19.2 ± 22.9 days). Likewise,
persistent candidaemia was less frequent
(p < 0.001) in period B (47 episodes; 47.4%) than
in period A (173 episodes; 93.0%). Concomitant
bacteraemia was documented in 29 (29.3%) epi-
sodes in period B, and in 91 (48.0%) episodes in
period A (p 0.002).
In total, 62 (63.0%) of 99 patients received
adequate antifungal therapy during period B. Of
these, 33 (56.0%) were treated with fluconazole,
eight (14.0%) with amphotericin B, and 16
(30.0%) with amphotericin B followed by flucon-
azole. The proportion of patients treated with
adequate antifungal therapy was significantly
higher in period B than in period A (76% vs.
41.0%; p < 0.001). Candidaemia was diagnosed
within 48 h of death in 12 (6.5%) patients in
period A, and in three (3.0%) patients in period B.
In period B, antifungal therapy was initiated
within 2.3 ± 3.0 days of the onset of the episode
of candidaemia (compared to 5.6 ± 8.4 days in
period A; p < 0.001).
During period B, 78 patients with CVC were
evaluable for catheter removal, and CVCs were
removed more frequently than during period A
(92% vs. 56.9%, p < 0.001). During period B, 72
patients with CVC underwent catheter removal,
of whom 41 (56.9%) had catheter-related candid-
aemia, whereas in period A, 52 (74.3%) of
70 patients had catheter-related candidaemia
(p 0.03). During period B, the 30-day crude
mortality rate (35%) of patients with candidaemia
was lower than in period A (44%), although this
difference was not statistically significant (p 0.20).
The exclusion of patients who died within 48 h
did not modify the mortality rate significantly
(41% in period A vs. 33% in period B; p 0.13).
DISCUSSION
This study analysed retrospectively the epidemi-
ological trends of candidaemia in patients admit-
ted to an Italian tertiary hospital during the
period 1992–2001. The overall annual incidence
of Candida BSI was high, but essentially stable
during the 10-year-period, and approached that
reported from the University of Iowa Hospitals in
the early 1990s [23]. In contrast, the annual
incidence of candidaemia was shown to be lower,
and decreasing over time, in a Swiss tertiary
hospital during the last decade [24]. Similarly, a
multicentre prospective study from a northern
Italian region reported a lower rate of candidae-
mia in comparison with the present data [14].
However, this survey was carried out in 35
hospitals, ranging in size from 135 to 1820 beds.
Rates of nosocomial candidaemia vary between
countries and hospitals according to a number of
variables, including type of institution, character-






(%) of isolates p
C. albicans 112 (53.8) 51 (48.1) NS
C. parapsilosis 47 (22.6) 19 (17.9) NS
C. glabrata 14 (6.7) 7 (6.6) NS
C. tropicalis 11 (5.3) 5 (4.7) NS
Othersa 24b (11.3) 24c (22.6) 0.010
Period A, 1992–1997; period B, 1998–2001; NS, not significant.
aCandida spp. other than C. albicans.
bC. pelliculosa (n = 8), C. lusitaniae (n = 3), C. humicola (n = 3), C. guilliermondii
(n = 1), C. incospicua (n = 1), C. famata (n = 1), C. norvegensis (n = 1) and non-
specified non-albicans Candida spp. (n = 6).
cC. pelliculosa (n = 6), C. guilliermondii (n = 5), C. humicola (n = 2), C. lusitaniae
(n = 2), C. famata (n = 2), C. rugosa (n = 2), C. kefyr (n = 1), C. norvegensis (n = 1), C.
krusei (n = 1) and non-specified non-albicans Candida spp. (n = 2).
Table 3. Candida spp. isolated from patients with candid-






ICUs No. (%) of
isolates
Period A Period B Period A Period B Period A Period B
C. albicans 6 (54.5) 8 (80.0) 36 (76.6)a 10 (31.2)a 70 (46.7) 33 (51.6)
Non-albicans
Candida spp.
5 (45.5) 2 (20.0) 11 (23.4) 22 (68.8) 80 (53.3) 31 (48.4)
Period A, 1992–1997; period B, 1998–2001; ICU, intensive care unit.
aStatistically significant difference (p < 0.001) between C. albicans and non-albicans
Candida spp. isolated in periods A and B.
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istics of patient populations, high-risk activities in
the context of invasive candidiasis, and the
frequency of performing blood cultures for diag-
nostic purposes.
Despite the absence of some of these data, the
present study reports on trends in candidaemia
from a single institution over a long period.
Approximately two-thirds of patients with can-
didaemia were hospitalised in ICUs, and the
incidence of candidaemia decreased significantly
among critically ill patients. To our knowledge,
this is the first European survey that clearly
demonstrates a decrease in the incidence of
hospital-acquired candidaemia among ICU
patients. A similar trend was observed during
1989–1999 among ICU patients in USA hospitals
reporting to the National Nosocomial Infection
Surveillance system [25]. Interestingly, that sur-
vey showed a decrease in the incidence of
C. albicans and an increase in C. glabrata BSIs. It
was suggested that these findings could be asso-
ciated with the increased use of prophylactic
fluconazole and the improved infection control
practices in USA hospitals. However, in the
present study, C. albicans remained the predom-
inant species, and no increase in dose-dependent
azole-susceptible or -resistant non-albicans Can-
dida spp., e.g., C. glabrata and C. krusei, was shown
to have occurred in recent years.
The overall use of fluconazole was high
throughout the entire study period, and exceeded
that reported by university hospitals in Switzer-
land and the USA during the 1990s [19,24,26].
Although data concerning ICU-specific flucona-
zole consumption were not available, the findings
suggested that the decreasing incidence of can-
didaemia should not be attributed to the use of
prophylactic fluconazole. However, infection con-
trol procedures, particularly those concerned with
the prevention of intravascular catheter-related
infections, have been considerably reinforced in
the ICUs of the hospital since 1995. Therefore, it
can be speculated that these measures alone
contributed to the decreasing incidence of can-
didaemia in this setting.
Comparing periods A (1992–1997) and B (1998–
2001), the majority of patients with candidaemia
in both periods were elderly, and the most
frequent underlying conditions were trauma,
solid neoplasia and abdominal diseases requiring
surgery. Few patients had AIDS, and none was
neutropenic or the recipient of a transplanted
organ. The findings confirm the importance of
nosocomial invasive candidiasis in a critically ill
non-immunosuppressed population [2]. More-
over, the decline in rapidly fatal underlying
diseases among patients with candidaemia dur-
ing the recent study period indicates the changing
baseline characteristics of this population in this
setting during the last decade.
C. albicans remained the predominant species in
both periods, followed by C. parapsilosis, C. glabrata
and C. tropicalis. Importantly, although no increase
in typically azole-resistant Candida spp., e.g.,
C. glabrata and C. krusei, occurred, a shift towards
other less common non-albicans Candida spp. was
observed in all patients, especially among those
hospitalised in surgical wards in recent years. The
altered distribution of Candida spp. has been
attributed by some authors to the widespread
use of azoles [6,7,18,25–27]; nevertheless, others
have failed to detect an increase in non-albicans
Candida spp., despite a significantly higher con-
sumption of fluconazole [16,19,24]. Use of flucon-
azole was considerable over the 10-year period of
the present survey, and none of the patients with
candidaemia received azole therapy or prophy-
laxis before the onset of candidaemia. Thus, the
increased frequency of some non-albicans Candida
spp. in this series did not seem to be attributable to
selective pressure from fluconazole.
As in other series reported from Canada, South
America and Europe [8,9], C. parapsilosis was the
predominant non-albicans Candida sp. in both
periods of the present survey. Despite recent
efforts, this finding highlights the continuing
inadequacy of infection control measures in some
areas of the hospital, since C. parapsilosis is
associated typically with the use of indwelling
CVCs and parenteral hyper-alimentation [7].
However, comparison of data from periods A
and B suggests a general improvement in infec-
tion control practices and clinical management of
candidaemia in this hospital in recent years. Thus,
CVC-related candidaemia, concomitant bacterae-
mia and episodes of persistent candidaemia were
less frequent in period B, and the duration of
episodes of candidaemia was substantially less in
recent years. These latter findings may be the
consequence of early treatment with adequate
antifungal regimens in a higher proportion of
patients, as well as CVC removal.
In summary, the overall incidence of nosoco-
mial candidaemia remained high between 1992
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and 2001; nevertheless, the incidence of this
severe infection decreased among critically-ill
patients, who represent the majority of patients
affected by candidaemia in this tertiary hospital.
More efficient implementation of appropriate
infection control measures probably contributed
to this trend. Although the consumption of
fluconazole was high, C. albicans remained the
predominant species and no emergence of typic-
ally azole-resistant non-albicans Candida spp. in
recent years was detected.
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